With more late-stage success, Quviviq could turn out to be sleeping giant

The Japanese business of Swiss biotech company Idorsia (SIX: IDIA) can boast positive top-line results from a Phase III trial of daridorexant.

The local study is investigating 25 and 50mg doses of the dual orexin receptor antagonist, which Idorsia hopes can improve on the safety profile of existing options.

The novel therapy works by stopping the activity of the neuropeptide orexin, a more targeted approach which could help avoid risks stemming from impairment to daytime functioning.